ClearPoint Neuro Files 8-K on Operations & Financial Condition

TL;DR

**ClearPoint Neuro just dropped an 8-K on its financials, standard stuff.**

AI Summary

ClearPoint Neuro, Inc. filed an 8-K on January 8, 2024, to report on its financial condition and operations. This filing is a standard disclosure, indicating the company is providing an update on its business activities. For investors, this matters because it signals that the company is adhering to regulatory requirements by keeping the market informed about its current state, which can influence stock valuation based on the disclosed information.

Why It Matters

This filing indicates ClearPoint Neuro is providing an update on its business, which is crucial for investors to assess the company's health and future prospects.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial condition and operations, not signaling any immediate new risks or opportunities.

Analyst Insight

A smart investor would note this as a routine compliance filing and await more detailed financial statements or operational updates for actionable insights.

Key Numbers

• 001-34822 — Commission File Number (Identifies ClearPoint Neuro's registration with the SEC.)
• 58-2394628 — IRS Employer Identification Number (Unique tax identifier for ClearPoint Neuro.)

Key Players & Entities

• ClearPoint Neuro, Inc. (company) — the registrant filing the 8-K
• January 8, 2024 (date) — date of earliest event reported and filing date
• Delaware (company) — state of incorporation for ClearPoint Neuro, Inc.
• 001-34822 (dollar_amount) — Commission File Number for ClearPoint Neuro, Inc.
• 58-2394628 (dollar_amount) — I.R.S. Employer Identification Number for ClearPoint Neuro, Inc.

Forward-Looking Statements

• ClearPoint Neuro will continue to file routine disclosures. (ClearPoint Neuro, Inc.) — high confidence, target: 2024-12-31

FAQ

Key Financial Figures

• $0.01 — ange on which registered Common Stock, $0.01 par value per share CLPT Nasdaq Capital

Filing Documents

• clpt-20240108.htm (8-K) — 27KB
• clpt-2024111xexx991.htm (EX-99.1) — 17KB
• clptinvestordeck_jpm2024.htm (EX-99.2) — 19KB
• clptinvestordeck_jpm2024001.jpg (GRAPHIC) — 84KB
• clptinvestordeck_jpm2024002.jpg (GRAPHIC) — 210KB
• clptinvestordeck_jpm2024003.jpg (GRAPHIC) — 100KB
• clptinvestordeck_jpm2024004.jpg (GRAPHIC) — 151KB
• clptinvestordeck_jpm2024005.jpg (GRAPHIC) — 111KB
• clptinvestordeck_jpm2024006.jpg (GRAPHIC) — 114KB
• clptinvestordeck_jpm2024007.jpg (GRAPHIC) — 105KB
• clptinvestordeck_jpm2024008.jpg (GRAPHIC) — 159KB
• clptinvestordeck_jpm2024009.jpg (GRAPHIC) — 231KB
• clptinvestordeck_jpm2024010.jpg (GRAPHIC) — 134KB
• clptinvestordeck_jpm2024011.jpg (GRAPHIC) — 129KB
• clptinvestordeck_jpm2024012.jpg (GRAPHIC) — 211KB
• clptinvestordeck_jpm2024013.jpg (GRAPHIC) — 103KB
• clptinvestordeck_jpm2024014.jpg (GRAPHIC) — 112KB
• clptinvestordeck_jpm2024015.jpg (GRAPHIC) — 116KB
• clptinvestordeck_jpm2024016.jpg (GRAPHIC) — 114KB
• clptinvestordeck_jpm2024017.jpg (GRAPHIC) — 211KB
• clptinvestordeck_jpm2024018.jpg (GRAPHIC) — 94KB
• image_0.jpg (GRAPHIC) — 54KB
• 0001285550-24-000016.txt ( ) — 3699KB
• clpt-20240108.xsd (EX-101.SCH) — 2KB
• clpt-20240108_lab.xml (EX-101.LAB) — 22KB
• clpt-20240108_pre.xml (EX-101.PRE) — 12KB
• clpt-20240108_htm.xml (XML) — 3KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On January 8, 2024, ClearPoint Neuro, Inc. (the "Company") issued a press release announcing its preliminary, unaudited financial results for the fourth fiscal quarter ended December 31, 2023. A copy of the press release is furnished herewith as Exhibit 99.1. The information in Item 2.02 of this Form 8-K, as well as Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On January 8, 2024, the Company posted an updated investor presentation to its website at http://ir.stockpr.com/clearpointneuro/investor-presentations. A copy of the investor presentation is being furnished herewith as Exhibit 99.2. The Company may use the investor presentation from time to time in conversations with analysts, investors and others. The information in Item 7.01 of this Form 8-K, as well as Exhibit 99.2 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The following exhibit is furnished herewith: Exhibit 99.1 Press Release dated J anuary 8, 2024 Exhibit 99.2 Investor Presentation dated Janua ry 8, 2024 Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 8, 2024 CLEARPOINT NEURO, INC. By: /s/ Danilo D'Alessandro Danilo D'Alessandro Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR